The purpose of the iniquitous writings of Mako is to scare shareholders and drive CTIX stock lower for the profit …
Enterprise
Development-stage biopharm company Cellceutix (CTIX) was also among the top dollar-stock winners Thursday, climbing more than 5% in midday trading to $1.62 on news that a U.S. district court granted Cellceutix's …
CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that Cellceutix has …
Cellceutix Corp. (OTCBB: CTIX) has six pharmaceutical compound candidates that ... Register now to create …
It indicates a vast market for the Cellceutix’s drug. In last trading session, the stock price of CTIX declined 0.36% to close the trading session at $2.74. The decline came at a share volume of 155,829 compared to average …
Cellceutix Corp (OTC: CTIX) continued is positive run regardless of the market ... Traders will be looking for the …
We have covered this one before on a number of occasions, and outlined it as a stock to watch throughout 2017 ... For the latest updates on CTIX, sign up below! Hemispherx BioPharma, Inc (NYSEMKT:HEB) took a hit of …